Current & Historical Practical Cure Projects

Tianhe Stem Cell Biotech, Hackensack NJ and Bejing China (5 trials)

Research Pathways:
Immune System Modification
Cell Regeneration

Phase I
Estimated completion December 2022

Phase II/III
Paused due to COVID-19

Description: Stem Cell Educator therapy is an immune system retraining method. The therapy attempts to stop the T1D autoimmune attack by modifying a person's white blood cells, so they no longer attack insulin-producing beta cells.

DRI/University of Miami, Miami, FL

Research Pathways:
Immune System Modification
Cell Regeneration

Phase I
Estimated completion December 2023

Phase II/III
Paused due to COVID-19

Description: Combination of Omega-3 and Vitamin D is designed to halt immune system response and preserve resdiual B-cell function. Two oral drugs.

Research Pathways:
Cell Transplant
Encapsulation

Phase I
Estimated completion January 2021

Phase II/III
Paused due to COVID-19

Description: Precursor cells, derived by an embryonic stem cell line, mature into unctional beta cells when implanted under the skin. Cells are protected by add encapsulation device.

Research Pathways:
Immune System Modification
Cell Regeneration

Phase I
Estimated completion December 2022

Phase II/III
Paused due to COVID-19

Description: Immunotherapy vaccine composed of the patient's cultured immune cells, a beta cell protein, and vitamin D3 touches the immune system to stop attacking beta cells and reducing inflammation.

Research Pathways:
Immune System Modification
Cell Regeneration

Phase I
Estimated completion December 2022

Phase II/III
Paused due to COVID-19

Description: Stem Cell Educator therapy is in immune system retaining method. The therapy attempts to stop the T1D autoimmune attack by modifying a person’s white blood cells, so they no longer attack insulin-producing beta cells.

Research Pathways:
Cell Regeneration
Immune System Modification

Phase II/III
Estimated completion March 2027

Description: The BCG vaccine is an avirulent tuberculosis strain historically given to protect against tuberculosis. Researchers believe administering a particular strain of BCG to people with T1D will balance the overactive autoimmune attack while regenerating the insulin-producing cells that remain present even in people who have had T1D for many years.

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Research Pathways:
Immune System Modification
Cell Regeneration

Phase I
Estimated completion December 2023

Phase I/II

Description: T1D patients are administered with their own white blood cells combined with Vitamin-D3 and cultivated with stem cells. The hope is that modifying the immune system in this way will induce beta cell regeneration.